TRANSFORM LDL-C risk, a new study to identify high-risk patients with established ASCVD
The American College of Cardiology has joined hands with Sanofi and Regeneron to conduct a new national study - TRANSFORM LDL-C Risk - to identify high-risk patients with atherosclerotic cardiovascular disease (ASCVD) and optimizing their access to the latest evidence-based treatments for low-density lipoprotein cholesterol (LDL-C) lowering and cardiovascular event risk reduction.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies